June 10, 2019

Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.

May 31, 2019

selectION, Inc. Announces $4.1M Series A Investment

May 7, 2019

Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting

March 13, 2019

EMA Grants Orphan Medicinal Product Designation for Retrotope’s RT001 in the Treatment of Infantile Neuroaxonal Dystrophy (INAD), a PLA2G6 associated neurodegeneration (PLAN)

March 7, 2019

GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement

January 3, 2019

Immusoft Raises $20 Million In Series B Financing

December 13, 2018

Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)

October 17, 2018

Immusoft Receives Rare Pediatric Disease Designation For Treatment Of MPS I

October 3, 2018

VelosBio raises $58M in Series A round for antibody-drug conjugate development

September 12, 2018

Oncternal Announces First Patient Dosed in Phase 1b Clinical Trial of Cirmtuzumab in Combination with Paclitaxel in Patients with Breast Cancer